Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph II Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition

Protocol: OSU-17013

Full Title

A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy.

Acute Myeloid Leukemia Leukemia